RESUMEN
Objective To detect the expression levels of renal tissue M-type phospholipase A2 receptor 1(PLA2R1) antigen and its antibody in the patients with membranous nephropathy(MN).Methods Fifty-eight cases of biopsy-proved idiopathic membranous nephropathy(IMN),fifteen cases of hepatitis B-associated membranous nephropathy(HBV-MN) and seventeen cases of V type lupus nephritis(V-LN) were selected.Renal tissue PLA2R1 antigen was detected by indirect immunofluorescence and colocaliazed with IgG4.Serum anti-PLA2R1 antibody was simultaneously examined.The expression difference of PLA2R1 antigen and antiPLA2R1 antibody in MN was analyzed.And the differences of clinical data were analyzed between PLA2R1 positive and negative patients.Results The PLA2R1 antibody was not found in the renal tissue and serum of the patients with LN and HBV-MN;PLA2R1 antigen was found in 81.03％ of IMN patients,and its antibody was found in serum of 70.69％ of IMN patients.PLA2R1 antigen and IgG4 co-localization all deposited along glomerular capillary loop presenting as fine granules.The 24 h urine protein level in the patients with PLA2R1 antigen deposition in renal tissues was higher than that in the patients without PLA2R1 deposition (P＜0.05),moreover serum albumin level was lower than that in the patients without PLA2R1 deposition(P＜0.05).Conclusion The sensitivity and specificity of renal tissue PLA2R1 antigen in the diagnosis of IMN are higher.The expression of PLA2R1 antigen in renal tissue by biopsy is significantly correlated with the clinical severity.
RESUMEN
Objective To investigate the different expressions of plasma M type phospholipase A2 receptor antibody and IgG subtypes deposition of kidney tissues in idiopathic membranous nephropathy and hepatitis B virus-associated membranous nephropa-thy,and to evaluate the significance of plasma M type phospholipase A2 receptor antibody and IgG subtypes in diagnosis of hepatitis B virus-associated membranous nephropathy.Methods Plasma samples were obtained from patients with idiopathic membranous nephropathy,hepatitis B virus-associated membranous nephropathy and minimal change disease,respectively,before immunosup-pressive therapy.Concentration of plasma M type phospholipase A2 receptor antibody was detected by sandwich ELISA and concen-tration of IgG subtypes were measured by immunofluorescence.Results Concentration of plasma M type phospholipase A2 receptor antibody was (15.4±7.2)μg/mL in idiopathic membranous nephropathy group,higher than that in the hepatitis B virus-associated membranous nephropathy group (10.3±5.7)μg/mL (P <0.01),between idiopathic membranous nephropathy group and hepatitis B virus-associated membranous nephropathy group.There was no distinct difference of IgG subtypes deposition in glomerlar capil-lary wall.Conclusion There is obvious clinical significance of concentration of plasma M type phospholipase A2 receptor antibody in differential diagnosis of idiopathic membranous nephropathy and hepatitis B virus-associated membranous nephropathy,while no distinct significance of IgG subtypes deposition.
RESUMEN
BACKGROUND: It is well known that chronic hepatitis B virus infection can commonly cause membranous nephropathy (MN), membranoproliferative glomerulonephritis type I (MPGN I), and rarely, membranoproliferative glomerulonephritis type III (MPGN III), which has the combined pathologic findings of MN and MPGN I. We report the clinical findings of MPGN III in patients with positive serum hepatitis B virus surface antigen. METHODS: The clinical findings of six MPGN III patients were investigated retrospectively to compare with those of eight MN and nineteen MPGN I patients with positive serum hepatitis B virus antigen. RESULTS: The mean age of MPGN III cases (29.7 years) was younger than that of MN (43.7 years) and MPGN I cases (44.4 years)(p<0.05). Males were predominant in all groups and the male/female ratio was 6:0 in MPGN III, 6:2 in MN, 17:2 in MPGN I group. The cases of nephrotic range proteinuria (4 out of 6 (66.7%) in MPGN III and 6 out of 8 (75%) in MN group) were more frequent than the 5 out of 19 (26.3%) found in the MPGN I group (p<0.05). The cases of HBe antigenemia were 5 out of 6 (83.3%) in MPGN III, 16 out of 19 (84.2%) in MPGN I and 5 out of 8 (62.5%) in the MN group. The cases of increased SGOT level were 5 out of 6 (83.3%) in MPGN III, 14 out of 19 (73.7%) in MPGN I and 4 out of 8 (50%) in the MN group. The cases of increased SGPT level were 5 out of 6 (83.3%) in MPGN III, 10 out of 19 (52.6%) in MPGN I and 2 out of 8 (25%) in the MN group. The cases of decreased serum C3 level were 4 out of 6 (66.7%) in MPGN III, 13 out of 19 (68.4%) in MPGN I and 3 out of 8 (37.5%) in the MN group. CONCLUSION: Patients with MPGN III show similar clinical findings to both the nephrotic proteinuria of MN patients and the decreased serum C3 level and increased SGOT/SGPT of MPGN I patients.